5 research outputs found
Sigma-1 receptors control neuropathic pain and macrophage infiltration into the dorsal root ganglion after peripheral nerve injury
Neuron-immune interaction in the dorsal root ganglia (DRG) plays a pivotal role in the neuropathic pain development after nerve injury. Sigma-1 receptor (Sig-1R) is expressed by DRG neurons but its role in neuropathic pain is not fully understood. We investigated the effect of peripheral Sig-1R on neuroinflammation in the DRG after spared (sciatic) nerve injury (SNI) in mice. Nerve injury induced a decrease in NeuN staining along with the nuclear eccentricity and ATF3 expression in the injured DRG. Sig-1R was present in all DRG neurons examined, and after SNI this receptor translocated to the periphery of the soma and the vicinity of the nucleus, especially in injured ATF3 + neurons. In WT mice, injured DRG produced the chemokine CCL2, and this was followed by massive infiltration of macrophages/monocytes, which clustered mainly around sensory neurons with translocated Sig-1R, accompanied by robust IL-6 increase and mechanical allodynia. In contrast, Sig-1R knockout (Sig-1R-KO) mice showed reduced levels of CCL2, decreased macrophage/monocyte infiltration into DRG, and less IL-6 and neuropathic mechanical allodynia after SNI. Our findings point to an important role of peripheral Sig-1R in sensory neuron-macrophage/monocyte communication in the DRG after peripheral nerve injury; thus, these receptors may contribute to the neuropathic pain phenotypeNeurofarmacología del dolor de la Universidad de Granada (CTS-109)FPU grants from the Spanish Ministry of Education, Culture and Sports.Spanish Ministry of Economy and Competitiveness (MINECO, grant SAF2016-80540-R)the Junta de Andalucía (grant CTS 109)Esteve PharmaceuticalsEuropean Regional Development Fund (ERDF
Urinary bladder sigma-1 receptors: A new target for cystitis treatment
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.phrs.2020.104724.No adequate treatment is available for painful urinary bladder disorders such as interstitial cystitis/bladder pain
syndrome, and the identification of new urological therapeutic targets is an unmet need. The sigma-1 receptor
(σ1-R) modulates somatic pain, but its role in painful urological disorders is unexplored. The urothelium expresses many receptors typical of primary sensory neurons (e.g. TRPV1, TRPA1 and P2X3) and high levels of σ1-
R have been found in these neurons; we therefore hypothesized that σ1-R may also be expressed in the urothelium and may have functional relevance in this tissue. With western blotting and immunohistochemical
methods, we detected σ1-R in the urinary bladder in wild-type (WT) but not in σ1-R-knockout (σ1-KO) mice.
Interestingly, σ1-R was located in the bladder urothelium not only in mouse, but also in human bladder sections.
The severity of histopathological (edema, hemorrhage and urothelial desquamation) and biochemical alterations
(enhanced myeloperoxidase activity and phosphorylation of extracellular regulated kinases 1/2 [pERK1/2]) that
characterize cyclophosphamide-induced cystitis was lower in σ1-KO than in WT mice. Moreover, cyclophosphamide-induced pain behaviors and referred mechanical hyperalgesia were dose-dependently reduced by σ1-R
antagonists (BD-1063, NE-100 and S1RA) in WT but not in σ1-KO mice. In contrast, the analgesic effect of
morphine was greater in σ1-KO than in WT mice. Together these findings suggest that σ1-R plays a functional role
in the mechanisms underlying cyclophosphamide-induced cystitis, and modulates morphine analgesia against
urological pain. Therefore, σ1-R may represent a new drug target for urinary bladder disorders.Spanish Ministry of Economy and Competitiveness (MINECO)
SAF2016-80540-REuropean Regional Development Funds (ERDF), Junta de Andalucia grant
CTS 109Esteve PharmaceuticalsInnovative Medicines Initiative 2 Joint Undertaking
777500European Union's Horizon 2020 research and innovation programmeEFPI
Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer
Financial support from the V Plan Propio (University of Seville). This work was also supported by Consejeria de Salud de la Junta de Andalucia (PI-0102-2017 and P18-HO-3882) and Instituto de Salud Carlos III (ISCIII) (Project PI19/01478) (FEDER).Introduction: Paclitaxel (PTX) is a cornerstone in the
treatment of breast cancer, the most common type
of cancer in women. However, this drug has serious
limitations, including lack of tissue-specificity,
poor water solubility, and the development of drug
resistance. The transport of PTX in a polymeric
nanoformulation could overcome these limitations.
Methods: In this study, PLGA-PTX nanoparticles
(NPs) were assayed in breast cancer cell lines, breast
cancer stem cells (CSCs) and multicellular tumor
spheroids (MTSs) analyzing cell cycle, cell uptake (Nile Red-NR-) and α-tubulin expression. In
addition, PLGA-PTX NPs were tested in vivo using C57BL/6 mice, including a biodistribution
assay.
Results: PTX-PLGA NPs induced a significant decrease in the PTX IC50 of cancer cell lines (1.31
and 3.03-fold reduction in MDA-MB-231 and E0771 cells, respectively) and CSCs. In addition,
MTSs treated with PTX-PLGA exhibited a more disorganized surface and significantly higher
cell death rates compared to free PTX (27.9% and 16.3% less in MTSs from MCF-7 and E0771,
respectively). PTX-PLGA nanoformulation preserved PTX’s mechanism of action and increased
its cell internalization. Interestingly, PTX-PLGA NPs not only reduced the tumor volume of treated
mice but also increased the antineoplastic drug accumulation in their lungs, liver, and spleen. In
addition, mice treated with PTX-loaded NPs showed blood parameters similar to the control mice,
in contrast with free PTX.
Conclusion: These results suggest that our PTX-PLGA NPs could be a suitable strategy for breast
cancer therapy, improving antitumor drug efficiency and reducing systemic toxicity without
altering its mechanism of action.V Plan Propio (University of Seville)Junta de Andalucia PI-0102-2017
P18-HO-3882Instituto de Salud Carlos IIIEuropean Commission PI19/0147
Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes
Paclitaxel (PTX), a drug widely used in lung cancer, has serious limitations including the development of peripheral neurotoxicity, which may lead to treatment discontinuation and therapy failure. The transport of PTX in large cationic liposomes could avoid this undesirable effect, improving the patient’s prognosis. PTX was encapsulated in cationic liposomes with two different sizes, MLV (180-200 nm) and SUV (80-100 nm). In both cases, excellent biocompatibility and improved internalization and antitumor effect of PTX were observed in human and mice lung cancer cells in culture, multicellular spheroids and cancer stem cells (CSCs). In addition, both MLV and SUV with a polyethylene glycol (PEG) shell, induced a greater tumor volume reduction than PTX (56.4 % and 57.1 % vs. 36.7 %, respectively) in mice. Interestingly, MLV-PEG-PTX did not induce either mechanical or heat hypersensitivity whereas SUV-PEG-PTX produced a similar response to free PTX. Analysis of PTX distribution showed a very low concentration of the drug in the dorsal root ganglia (DRG) with MLV-PEG-PTX, but not with SUV-PEG-PTX or free PTX. These results support the hypothesis that PTX induces peripheral neuropathy by penetrating the endothelial fenestrations of the DRG (80-100 nm, measured in mice). In conclusion, our larger liposomes (MLV-PEG-PTX) not only showed biocompatibility, antitumor activity against CSCs, and in vitro and in vivo antitumor effect that improved PTX free activity, but also protected from PTX-induced painful peripheral neuropathy. These advantages could be used as a new strategy of lung cancer chemotherapy to increase the PTX activity and reduce its side effects.Junta de Andalucía
P11-CTS-7649
PI-0102-2017
P18-TP-3882
CTS-107CTS-107 GroupInstituto de Salud Carlos III
PI19/0147
Uso del ácido maslínico para el tratamiento de dolores de naturaleza nociceptiva, inflamatoria y neurogénica
Número de publicación: ES2333638 B2. Número de solicitud: 200901745.Uso del ácido maslínico para el tratamiento de dolores de naturaleza nociceptiva, inflamatoria y neurogénica. La presente invención se refiere al uso del ácido maslínico y cualquiera de sus derivados para el tratamiento de procesos patológicos dolorosos, de naturaleza (1) nociceptiva, (2) inflamatoria o (3) neurogénica, por cualquier medio galénicamente aceptable y muy especialmente por vía tópica, incluyendo composiciones que contengan ácido maslínico, cualquiera de sus derivados, o mezclas naturales, sintéticas o semisintéticas ricas en maslínico o sus derivados.Universidad de Granad